These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35997216)

  • 21. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
    Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
    Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
    Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
    J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles.
    Thomsen LH; Kesmodel US; Erb K; Bungum L; Pedersen D; Hauge B; Elbæk HO; Povlsen BB; Andersen CY; Humaidan P
    Hum Reprod; 2018 Aug; 33(8):1506-1516. PubMed ID: 29955789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
    Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
    Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
    Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
    Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
    Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching.
    Dong L; Lian F; Wu H; Xiang S; Li Y; Wei C; Yu X; Xin X
    BMC Pregnancy Childbirth; 2022 Jul; 22(1):583. PubMed ID: 35869444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of luteal HCG supplementation in GnRH-agonist-triggered fresh embryo transfer cycles: a randomized controlled trial.
    Svenstrup L; Möller S; Fedder J; Pedersen DE; Erb K; Andersen CY; Humaidan P
    Reprod Biomed Online; 2024 May; 48(5):103415. PubMed ID: 38452605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.
    Zhang Y; Zhao W; Han Y; Chen X; Xu S; Hu Y; Diao H; Zhang C
    Reprod Biol Endocrinol; 2022 Sep; 20(1):140. PubMed ID: 36123706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The early luteal hormonal profile in IVF patients triggered with hCG.
    Vuong LN; Ho TM; Pham TD; Ho VNA; Andersen CY; Humaidan P
    Hum Reprod; 2020 Jan; 35(1):157-166. PubMed ID: 31967304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support.
    Kol S; Segal L
    Reprod Biomed Online; 2020 Nov; 41(5):854-858. PubMed ID: 32873493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve.
    Ren YM; Wang YB; Fu M; Zhang QX; Shen H; Han HJ; Gao FM
    Curr Med Sci; 2022 Oct; 42(5):1066-1070. PubMed ID: 35997911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dydrogesterone supplementation in addition to routine micronized progesterone administration for luteal support in cycles triggered with lone GnRH agonist results in an acceptable pregnancy rate and avoids the need to freeze embryos.
    Safrai M; Hertsberg S; Ben-Meir A; Reubinoff B; Imbar T; Mordechai-Daniel T; Alexander S
    Minerva Obstet Gynecol; 2023 Feb; 75(1):39-44. PubMed ID: 34904585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.